Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.79 |
| ▸ | MAPT | P10636 | 2/20 | 0.79 |
| ▸ | TP53 | P04637 | 1/20 | 0.79 |
| ▸ | PKM | P14618 | 3/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 8/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247294 | 0.86 | PKM (1.00) | SMN1; SMN2MAPTTP53PKMKDM4E | |
| SCHEMBL5915339 | 0.84 | LSS (0.79) | SMN1; SMN2KDM4ELMNAALDH1A1MAPK1 | |
| SCHEMBL27698589 | 0.84 | PKM (0.65) | SMN1; SMN2MAPTTP53PKMKDM4E | |
| SCHEMBL13973341 | 0.83 | SMN1; SMN2 (0.74) | SMN1; SMN2MAPTTP53PKMKDM4E | |
| SCHEMBL13959171 | 0.82 | SMN1; SMN2 (0.73) | SMN1; SMN2MAPTTP53PKMKDM4E | |
| SCHEMBL12346558 | 0.81 | SMN1; SMN2 (0.87) | SMN1; SMN2MAPTTP53PKMKDM4E | |
| SCHEMBL4616802 | 0.80 | LMNA (0.73) | SMN1; SMN2MAPTTP53PKMKDM4E | |
| SCHEMBL12431863 | 0.79 | HDAC3 (0.83) | SMN1; SMN2MAPTTP53PKMKDM4E | |
| SCHEMBL1874860 | 0.79 | PTPN7 (0.66) | SMN1; SMN2MAPTTP53PKMKDM4E | |
| SCHEMBL108678 | 0.79 | KDM4E (0.70) | KDM4EMAPK1TSHRCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758884-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| WO-2005113542-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | BACE1, BACE2, APH1B | SMN1; SMN2 640/4885MAPT 374/4885TP53 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.